CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells-Reference-Cited by-同舟云学术

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells

Published:2013-12 Issue:12 Volume:2 Page:e26968
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Strachan Debbie C,Ruffell Brian,Oei Yoko,Bissell Mina J,Coussens Lisa M,Pryer Nancy,Daniel Dylan

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/onci.26968

Reference44 articles.

1. Macrophages, innate immunity and cancer: balance, tolerance, and diversity

2. Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility

3. Trophic macrophages in development and disease

4. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

5. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

Cited by 318 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential applications of macrophages in cancer immunotherapy;Biomedicine & Pharmacotherapy;2024-09

2. Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization;Cell Reports Medicine;2024-08

3. Controlling tumor progression and recurrence in mice through combined treatment with a PD-L1 inhibitor and a designer Salmonella strain that delivers GM-CSF;Acta Pharmaceutica Sinica B;2024-07

4. Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts;International Journal of Molecular Sciences;2024-06-26

5. Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors;Frontiers in Immunology;2024-06-25